olaparib zytiga for metastatic castrate-resistant prostate cancer | learn about clinical trials
Published 4 years ago • 4.5K plays • Length 3:48Download video MP4
Download video MP3
Similar videos
-
5:14
olaparib and keytruda for advanced prostate cancer | | learn about clinical trials
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
5:05
castrate resistant, non-metastatic prostate cancer (m0 state) | prostate cancer staging guide
-
4:42
androgen annihilation in high-risk biochemically relapsed prostate cancer | learn clinical trials
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
14:53
finding & choosing clinical trials for #prostatecancer | #markscholzmd #alexscholz #pcri
-
1:49
parpi olaparib for the targeted treatment of metastatic prostate cancer
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
4:23
apalutamide for high-risk prostate cancer | learn about clinical trials
-
3:24
what is lynparza and how does it work in prostate cancer? | ask a prostate expert, mark scholz, md
-
1:22:50
demystifying prostate cancer clinical trials
-
1:15
exciting times for hormone-sensitive prostate cancer treatment
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
0:36
treating patients with progressive metastatic castration-resistant prostate cancer
-
5:40
parp inhibitors in advanced prostate cancers
-
11:49
brca & parp inhibitors: targeted chemotherapy | #markscholzmd #alexscholz @pcri